Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study

Table 1 Main features of the study population at baseline

Baseline feature	Dual therapy	Triple therapy	Normal range	P value
Age (yr)	51.82 ± 11.40	56.65 ± 8.24		0.16
BMI	24.65 ± 3.45	26.17 ± 3.55	18-25	0.08
Male sex	40/25	10/10
Albumin (g/dL)	4.11 ± 0.34	4.08 ± 0.49	3.5-5.0	0.95
Bilirubin (mg/dL)	0.78 ± 0.41	1.05 ± 0.21	0.3-1	0.06
Platelets (× 109/L)	190.29 ± 60.04	168.16 ± 51.08	140-440	0.18
ALT (U/L)	116.75 ± 88.69	82.88 ± 47.86	5-40	0.28
GGT (U/L)	72.16 ± 80.53	93.38 ± 77.62	10-40	0.06
C/T or T/T IL28B genotype	19.50%	100%
Liver stiffness (kPa)	8.61 ± 5.79	13.29 ± 8.57		0.002
HCV genotypes 1/4, n (%)	24 (36.92)	20 (100)
HCV genotypes 2/3, n (%)	41 (63.08)
HCV RNA level (IU × 1000)	3459.135 ± 5541.24	4924.462 ± 6799.737		0.72

BMI: Body mass index; ALT; Alanine aminotransferase; GGT; Gamma glutamyl transpeptidase; HCV: Hepatitis C virus.

Table 2 Univariate analysis of negative prognostic factors of sustained virologic response in both dual and triple therapy

	Dual therapy (P value)	Triple therapy (P value)
Male sex	0.33	0.39
Age ≥ 55 yr	0.40	0.47
HCV genotype 1 and 4	0.46	-
Liver stiffness > 12 kPa	0.03	0.001
C/T or T/T IL28B genotype	0.12	-
> 500000 IU HCV RNA titre	0.30	0.06

-: Omitted because of collinearity. HCV: Hepatitis C virus.

Table 3 Multivariate analysis of negative prognostic factors of sustained virologic response in both dual and triple therapy

	Dual therapy (P value)	Triple therapy (P value)
Male sex	0.465	0.913
Age ≥ 55 yr	0.465	0.954
HCV genotypes 1 and 4	0.622	-
Liver stiffness > 12 kPa	0.733	0.049
C/T or T/T IL28B genotype	0.622	-
> 500000 IU HCV RNA titre	0.317	0.532

-: Omitted because of collinearity. HCV: Hepatitis C virus.